Redwood AI Corp. (CSE: AIRX) (OTCQB: RDWCF) (Frankfurt: Y0N) (WKN: A422EZ) has been named a co-applicant in a competitive Terry Fox Research Institute grant awarded to advance Onco-Innovations’ SynoGraph(TM) oncology platform. The project, titled “Causal AI to Predict First-in-Human Clinical Outcomes from Preclinical and Real-World Clinico-Genomic Data,” will investigate whether causal AI can improve predictions of first-in-human clinical outcomes using preclinical and real-world clinico-genomic data.
The grant, announced on September 22, names Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) as lead applicant, with Redwood AI, the Michael Smith Genome Sciences Centre and the Centre de recherche du CHU de Québec-Université Laval as co-applicants. The project has an estimated budget of $3.5 million, with the grant reimbursing eligible costs up to 25% of that amount. Redwood AI will contribute proprietary data integration and physicochemical modelling methods to expand SynoGraph’s predictive capabilities. Academic partners will provide clinico-genomic and imaging data for research using federated learning, which is intended to support analysis while protecting data privacy.
This collaboration matters because it brings together industry and academic expertise to tackle a critical bottleneck in oncology: predicting how experimental therapies will perform in humans before costly and time-consuming clinical trials. By leveraging causal AI and real-world data, the project could lead to more efficient drug development and better outcomes for cancer patients. Redwood AI’s involvement underscores the growing role of artificial intelligence in life sciences and the potential for cross-sector partnerships to drive innovation in critical industries.
Redwood AI is the developer of an AI-powered platform for real-world applications across multiple critical industries. The company’s participation in this Terry Fox-funded project highlights its commitment to advancing AI solutions that address complex challenges. For investors and industry observers, the grant serves as external validation of Redwood AI’s technology and its ability to collaborate on high-impact research. The latest news and updates relating to RDWCF are available in the company’s newsroom at https://ibn.fm/RDWCF.
The announcement was disseminated by AINewsWire, a specialized communications platform focused on advancements in artificial intelligence. AINewsWire is one of 75+ brands within the Dynamic Brand Portfolio at IBN, which provides access to wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, press release enhancement, social media distribution and tailored corporate communications solutions.
